Previous 10 | Next 10 |
The following slide deck was published by Exact Sciences Corporation in conjunction with their 2022 Q3 earnings call. For further details see: Exact Sciences Corporation 2022 Q3 - Results - Earnings Call Presentation
Exact Sciences ( NASDAQ: EXAS ) is up 7% in after-hours trading after boosting its 2022 revenue guidance and posting Q3 2022 beats on the bottom and top lines. The company now expects revenue of $2.025B-$2.042B, up from an earlier estimate of $1.980-$2.022 (co...
Exact Sciences press release ( NASDAQ: EXAS ): Q3 GAAP EPS of -$0.84 beats by $0.23 . Revenue of $523.07M (+14.6% Y/Y) beats by $19.95M . Total third quarter revenue, excluding COVID-19 testing, increased 20 percent compared to the third quarter of 2021, with S...
Exact Sciences Announces Third Quarter 2022 Results PR Newswire Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability Third quarter highlights Total third quarter revenue, excluding COVID-19 testing, increased 20 percent c...
Summary The FDA is working with congress to extend its regulatory arm over the gene testing market. Veracyte's products are marketed as LDTs and are not approved by the FDA. Regulatory risk weighs against Veracyte's relatively low cash burn and robust balance sheet, underpinni...
Summary Mainz Biomed is a German developer of genetic tests for various diseases, primarily cancer. At the moment, the company has one main product, ColoAlert, a colorectal cancer test that is so far only approved in some non-US countries. For the coming quarters, the investme...
Summary The FDA is preparing to extend its regulatory arm over LDTs. The potential for negative regulatory intervention puts OCX's strategy into serious question. OCX must navigate the new regulations and the limited resources that come with being a small-cap company while try...
It's difficult to predict precisely what the world will look like in five years. But here is a prediction that seems reasonably safe; in half a decade, equity markets will be up from where they are today. The historical record strongly suggests that this forecast will come to pass. And whil...
Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting PR Newswire Data presentations include positive impact of eliminating patient cost for follow-up colonoscopies, shif...
There's big news for Guardant Health (NASDAQ: GH) shareholders today -- but disappointing news also. This morning, analysts at investment bank Craig-Hallum announced a switch in their bets on cancer-screening biopsy companies, downgrading shares of Exact Sciences (NASDAQ: ...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...